[{"orgOrder":0,"company":"BiPER Therapeutics","sponsor":"MEDIN Fund Management Company","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Miscellaneous","year":"2025","type":"Financing","leadProduct":"BPR001","moa":"GRP78 | BiP","graph1":"Oncology","graph2":"IND Enabling","graph3":"BiPER Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BiPER Therapeutics \/ MEDIN Fund Management Company","highestDevelopmentStatusID":"5","companyTruncated":"BiPER Therapeutics \/ MEDIN Fund Management Company"}]

Find Clinical Drug Pipeline Developments & Deals by BiPER Therapeutics

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Global ChemShow
                          Not Confirmed
                          Global ChemShow
                          Not Confirmed

                          Details : The financing for BPR001 will support the development of gastrointestinal cancer treatments targeting GRP78 | BiP.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Undisclosed

                          December 02, 2025

                          Lead Product(s) : BPR001

                          Therapeutic Area : Oncology

                          Highest Development Status : IND Enabling

                          Sponsor : MEDIN Fund Management Company

                          Deal Size : Undisclosed

                          Deal Type : Financing

                          blank